These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 20838744

  • 1. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
    Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, Sibbing D.
    Thromb Haemost; 2010 Dec; 104(6):1193-200. PubMed ID: 20838744
    [Abstract] [Full Text] [Related]

  • 2. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.
    Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
    [Abstract] [Full Text] [Related]

  • 3. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S.
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [Abstract] [Full Text] [Related]

  • 4. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA.
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [Abstract] [Full Text] [Related]

  • 7. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P, Eshtehardi P, Abrecht L, Zwahlen M, Schmidlin K, Windecker S, Meier B, Haeberli A, Hess OM.
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM.
    Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H, Lask S, Engelhardt A, Mügge A.
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [Abstract] [Full Text] [Related]

  • 13. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.
    J Am Coll Cardiol; 2007 Feb 13; 49(6):657-66. PubMed ID: 17291930
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chen YG, Xu F, Zhang Y, Ji QS, Sun Y, Lü RJ, Li RJ.
    Chin Med J (Engl); 2006 Jan 05; 119(1):32-6. PubMed ID: 16454979
    [Abstract] [Full Text] [Related]

  • 16. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL.
    Thromb Haemost; 2007 Feb 05; 97(2):282-7. PubMed ID: 17264958
    [Abstract] [Full Text] [Related]

  • 17. Association of recurrent cerebral infarction with adenosine diphosphate- and collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin.
    Abumiya T, Houkin K.
    J Stroke Cerebrovasc Dis; 2011 Feb 05; 20(4):319-23. PubMed ID: 20634093
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.
    Thromb Haemost; 2010 Jan 05; 103(1):151-9. PubMed ID: 20062919
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM, Claeys MJ, Haine S, Miljoen H, Bosmans JM, Vertessen F, Kluppels K, Van der Planken M, Vrints CJ.
    Am Heart J; 2010 Mar 05; 159(3):434-8. PubMed ID: 20211306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.